Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (373)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 101 to 125 of 383
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Efgartigimod for treating generalised myasthenia gravis [ID4003]
Technology appraisal guidance
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Technology appraisal guidance
TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]
Technology appraisal guidance
TBC
Elafibranor for treating primary biliary cholangitis [ID6331]
Technology appraisal guidance
TBC
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]
Technology appraisal guidance
5 June 2024
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
Technology appraisal guidance
TBC
Encorafenib with binimetinib for BRAF V600E mutation-positive advanced non-small-cell lung cancer ID6177
Technology appraisal guidance
TBC
Endometriosis: diagnosis and management - diagnosing endometriosis
NICE guideline
10 July 2024
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
Interventional procedures guidance
TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Technology appraisal guidance
15 June 2022
Epilepsies in children, young people and adults (extraordinary review)
NICE guideline
TBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]
Technology appraisal guidance
14 August 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
Technology appraisal guidance
TBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]
Technology appraisal guidance
TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
Technology appraisal guidance
29 January 2025
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]
Technology appraisal guidance
TBC
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]
Technology appraisal guidance
11 September 2024
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Technology appraisal guidance
TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
Technology appraisal guidance
TBC
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]
Technology appraisal guidance
TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests
Diagnostics guidance
TBC
Falls: assessment and prevention in older people and people 50 and over at higher risk (update)
NICE guideline
26 March 2025
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]
Technology appraisal guidance
14 August 2024
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Technology appraisal guidance
16 October 2024
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
Technology appraisal guidance
22 May 2024
Previous page
1
…
3
4
Current page
5
6
7
…
16
Page
5
of
16
Next page
Results per page
10
25
50
All
Back to top